Bryan Tagge, M.D.

CURRENT CLINIC ADDRESS

2001- Present
Ear, Nose, and Throat Center
22 South 900 East
Salt Lake City, Utah 84102

Draper Office
756 East 12200 South
Draper, Utah 84020

Park City Office
1820 Sidewinder Dr Suite 110
Park City, Utah 84060

MEDICAL LICENSE

State of Utah (#4881588-1205)

UNDERGRADUATE EDUCATION

1987-1990
University of Utah
Salt Lake City, Utah
B.S. Biology

GRADUATE EDUCATION

1991-1995
University of Utah
Salt Lake City, Utah
Doctor of Medicine

INTERNSHIP

1995-1996
Riverside Methodist Hospital
Department of General Surgery
Columbus, Ohio
General Surgery

RESIDENCY

1996-2000
Ohio State University
Columbus, Ohio
Otolaryngology
Head and Neck Surgery

PROFESSIONAL EXPERIENCE

2001- Present
Ear, Nose, and Throat Center Salt Lake City, Utah
Staff Physician

ADMINISTRATIVE EXPERIENCE

1994-1995
University of Utah
American Medical Association! Medical
Student Section, President

1994-1995
University of Utah
Student Advisory Committee Promotion-Retention- Tenure

1994-1995
Utah Medical Association Board of Trustees

1993-1994
Salt Lake County Medical Society Medical Student Representative

1992-1994
University of Utah
American Medical Association
Medical Student Section, Vice President

1992-1995
Utah Medical Association Delegate

1983-1984
Skyline High School Studentbody President

HONORS AND CERTIFICATIONS

2000
1st Place, Resident Research Competition Annual William Saunders Meeting

1993
University of Utah Alpha Omega Alpha Senior Medical Student

1994-1995
Salt Lalce County Alliance Scholarship

1994
Student Excellence Award

1992-1993
Webster Scholarship

1993-1994
University of Utah
Honors Achievement (top 10%) in 18 Courses and Clinical Rotations

1990
University of Utah
Golden Key National Honor Society

1987-1990
University of Utah Leadership Scholarship

1984
Skyline High School National Honor Society

HOSPITAL PRIVILEGES

LDS Hospital
Salt Lake City, Utah

Primary Children’s Medical Center z
Salt Lake City, Utah

Salt Lake Regional Medical Center
Salt Lake City, Utah

St. Mark’s Hospital
Salt Lake City, Utah

PROFESSIONAL MEMBERSHIPS

American College of Surgeons, Candidate Member
American Academy of Otolaryngology Head and Neck Surgery, Member
American Academy of Facial Plastic and Reconstructive Surgery, Resident Member
American Medical Association, Member

PUBLICATIONS

Alderson KA, Anderson RL, Holds J, Tagge BT. Botulinum-induced alteration of nerve muscle interactions in the human orbicularis oculi following treatment for blepharospasm. J Neurology.
41(11): 1800-5,1991.

Hartog J, Tagge BT, Hardy S, Creel DS. Distraction osteogenesis in the craniofacial skeleton in rabbits using an adjustable internal fixation device. Submitted to J Cleft Palate-Craniofacial.

PRESENTATIONS

Tagge BT. “Transtympanic Myringoplasty.” Combined Otolaryngological Spring Meeting
(COSM), April, 2000.

Tagge BT. “Techniques in Lip Reconstruction.” Grand Rounds, Department of Otolaryngology,
The Ohio State University Medical Center, June 3, 1998.

Tagge BT. “Contemporary Treatment of Snoring and Obstructive Sleep Apnea.” Grand Rounds, Department of Otolaryngology, The Ohio State University Medical Center, March 18,1998.

Tagge BT. “ReviewofTympanoplasty.” Grand Rounds, Department of Otolaryngology, The Ohio State University Medical Center, December 9, 1997.

Tagge BT. “Blepharoplasty: Review and 1990’s Update.” Grand Rounds, Department of
Otolaryngology, The Ohio State University Medical Center, October 8, 1997.

Tagge BT, Olson RJ, Mammalis NM. Ethylene Oxide resterilization of corneal storage chambers used by Eye Banks: A potential cause of graft failure in corneal transplants. Presented at Research
Day, Department of Opthalmology, University of Utah, March 1993

Tagge BT, Hartog J, Hardy S, Creel DS. Distraction osteogenesis in the craniofacial skeleton using an intemal fixation device. Presented at the American Federation for Clinical Research, Morphogenesis/Dysmorphology section in Carmel, California, February 12, 1993.

PAST AND ONGOING RESEARCH

Efficacy and Safety of XXX in the Treatment of Acute Peripheral Tinnitis 2 (TACTT2). 2014.
Sponsored by Auris.

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b Study of OTO-104 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere’s Disease.
2013. Sponsored by Otonomy.

A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Phase 3 Study of OTO- 201 Given As a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement. 2013. Sponsored by atonomy.

Proof-of-Concept of Single Application of XXX Otic Suspension in Treatment of Acute Otitis media with Tympanostomy Tubes Compared to CIPRODEX (BID for 7 days). 2013. Sponsored by Alcon.

A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety oflntranasal Administration of 100,200, and 400 µg of XXX Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects with Bilateral Nasal PolyposisFollowed by an 8-Week Open-Label Extension Phase to Assess Safety. 2013. Sponsored by Optinose.

A 12- Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administion of µg of XXX Twice a Day (BID) Usinga Novel Bi-Directional Device in Subjects with Chronic Sinusitis
With or Without Nasal Polyps. 2013. Sponsored by Optinose.

A 3-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 µg of XXX Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects with Chronic
Sinusitis With or Without Nasal Polyps. 2013. Sponsored by Optinose.

A Clinical Evaluation ofthe Safety and Efficacy ofthe Steroid-Releasing XXX Sinus Implant Used in post-Sinus Surgery Patients with Recurrent Sinus Obstruction. 2013. Sponsored by Intersect ENT.

A Clinical Evaluation of the Mechanical Contribution of XXX Sinus Implant in Improving Sinus Patency and Symptoms When Used in post-Sinus Surgery Patients with Recurrent Ethmoid Sinus Obstruction-Ethmoid Sinus Patency (ESP) Pilot Study. 2012. Sponsored by Intersect ENT.

A Clinical Evaluation of the Steroid-Eluting S8 Sinus Implant Used Following Endoscopic Sinus Surgery (ESS) in Patients with Chronic Sinusitis-XXX Surgical Pilot Study. 2012. Sponsored by Intersect ENT.

A Clinical Evaluation of XXX in Jmproving Sinus Patency and Symptoms Wben Used in post-Sinus Surgery patients with Recurrent Ethmoid Sinus Obstruction. 2012. Sponsored by Intersect ENT.

A Clinical Evaluation of XXX Used Following Endoscopic Sinus Surgery in Patients with Chronic
Sinusitis. 2012. Sponsored by Intersect ENT.

A Clinical Evaluation of XXX in Jmproving Sinus patency and Symptoms When Used in post-Sinus
Surgery Patients with Recurrent Ethmoid Sinus Obsb’UCtion. Sub Investigator, Phase 2, 2012.
Sponsored by Intersect ENT.

A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of XXX plus XXX compared to XXX and to XXX in the Treatment of Acute Otitis Media with Tympanostomy Tubes (AOMT) in pediatric Patients. Sub Investigator, Phase 3, 2012-2013. Sponsored by Laboratorios SALVAT, S.A.

Safety and Efficacy Evaluation of Topical XXX Otic SlL’lpension in the Treatment of Acute Otitis Extema. Principal Investigator, Phase 3, 2012. Sponsored by Alcon Research, Ltd

A Clinical Evaluation of the XXX Used in Post-Sinus Smgery Patients with Recunent Sinus
Obstruction. Sub Investigator,Phase 3,2011-2012. Sponsored by Intersect ENT.

Topical Treatment of Acute Otitis Media through Tympaostomy Tubes (AOMT) and its Effect on Microbial Flora Distal to the Site of Infection. Principal Investigator, Phase 3, 2011-2012.
Alcon Research, Ltd.

Safety and Efficacy Evaluation of Topical XXX in the Treatment of Acute Otitis Media with Otorrhea in T ympanostomy Tubes. Principal lnvesti gator, Phase 3, 2010-201 l. Sponsored by Alcon Research Ltd.

Natural History Study ofIncidcnce of Otorrhea Following TympanoStomy Tube Insertion in a Cohort of Cbildren Aged 6 Months to 12 Year.l. Principal Investigator , Natural History, 2010-2011. Sponsored by Alcon Research Ltd.

A Clinical Evaluation of XXX wben used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis. Sub Investigator, 2009-2010. Sponsored by Intersect ENT.

Safety of XXX in Patients with Perennial Allergi c Rhiniti s. Sub Investigator, Phase 3, 2009-2010. Alcon Research, Ltd.

A Clinical Evaluation of XXX When Used Following Functional Endoscopic Sinus Surgery in
Patients with Chronic Sinusitis. Sub Investigator 2009. Sponsored by Sinexus Inc.

A Clinical Evaluation of XXX When Used Following Functioual Endoscopic Sinus Surgery in Patients with Chronic Rhinosinusitis. Sub Investigator, 2008-2009. Sponsored by SinCXUS Inc.

Safety and Efficacy of XXX in the Treatt)lent of Acute Otiti’ Extetna. Principal Investigator, Phase
3, 2008. Sponsored by Alcon Research Ltd.

Safety and Efficacy of XXX in the Tteatt)lent of Acute Otitis Media with Ototrhea tilTOUgh Tympanostomy Tubes. PrincipallnvestigaiOt, Phase 3, 2006. Sponsored by Alcon Research Ltd

xxx vs. XXX Trial to assess the safety and efficacy of XXX in the treatt)lent of subjects with acute diffuse otitis extema in children, adolescents, and adults. Sub Investigalor, 2004. Laboratorios SAL VAT, S.A. through P AREXEL.

An open uncontrolled trial to evaluate the time to bacterial eradication alld key symptom reUefin the treatment of Acute Bacterial Maxillary Sinusitis with XXX QD. Sub Investigator, 2004. Sponsored by Bayer Corporation.

XXX v,. XXX for the Ttellimem of Acute Bacterial Sinusitis. Sub Investigator, Phase 3, 2003-2004.
Sponsored by Pfizer.

XXX vs. XXX vs. XXX in Subjects with Perennial Allergic Rhinitis. Sub Investigator, phase 3,
2002-2003. Sponsored by Aventis Pharmaceuticals through Quintiles.

XXX on Episodes of Acute Sinusitis when Administered Ili the First Si go of Sinus SymptoUlli. Sub
lnvest.igllior, Phase 2, 2002. Sponsored by Pfizer thmugh West p/ulrmaceuticals
xxx for 4 Days vs. XXX for 6 Days for the Treatt)lent of Acute Bacterial Sinusitis. Sub
Investigator, Phase 3,2002. Sponsored by Pfizer through PPD Development.

XXX for 7 Days in the Treatment of Acute Bacterial Sinusitis. Sub Investigator, Ph””e 3, 200!.
Sponsored by Bayer Corporation through Paragon Biomedical.

XXX in the Tteatment of Acute Bacterial Sinusitis. Sub Investigator, Phase 2, 2000. Sponsored by Abbott Laboratories through The Phoenix.

Transtympanic Myringoplasty
post-treatment Instructions After particle Repositioning Maneuver in the Treatment in Benign Paroxysmal Vertigo.